Puma Biotechnology | PBYI - Gross Profit On Sales


Puma Biotechnology reported $20.32M in Gross Profit on Sales for its fiscal quarter ending in September of 2024.





Gross Profit On Sales Change Date
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Amgen USD 6.89B 415M Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Exelixis USD 590.86M 18.68M Mar/2026
Gilead Sciences USD 5.52B 791M Mar/2026
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Incyte USD 1.17B 217.51M Mar/2026
MacroGenics USD 31.11M 30.14M Dec/2025
Moderna USD -566M 792M Mar/2026
Novartis USD 10.07B 184M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
Takeda JPY 688.84B 101.71B Mar/2026
TG Therapeutics USD 171.41M 16.98M Mar/2026
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026